AURA BIOSCIENCES INC (AURA)
Health Care · Oncolytic immunotherapy · NASDAQ
A clinical-stage biotech developing VDC-based oncolytic immunotherapies targeting solid tumors, with bel-sar in clinical trials for choroidal melanoma and other cancers.
What AURA BIOSCIENCES INC does
Aura Biosciences is a clinical-stage biopharmaceutical company developing VDC (Virus-Directed Cytolytic) therapy platform and its lead candidate bel-sar, an investigational oncolytic immunotherapy designed to treat choroidal melanoma and other solid tumors. The company is currently conducting clinical trials for bel-sar in early choroidal melanoma and expanding into additional oncology indications including bladder cancer and choroidal metastases. Aura has generated no product revenue to date and is primarily advancing its research and development programs toward regulatory approval.
Themes: ["Oncolytic immunotherapy"]
Fundamentals
- Price$7.00 as of 2026-07-09 close
- Market cap$724M as of 2026-07-10
- 1-year return+16.0% as of 2026-07-09 close
- ROE-78.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.40 as of 2026-07-10
Key risks (from latest filing)
["No approved products or revenue; company faces substantial risk regarding ability to continue as a going concern given accumulated deficit of $480.4 million and ongoing operating losses ($106.2 million in 2025)."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.